• Too Sexy for Your Data?

    Sep 26, 2012, 12:05 PM by Michael Croft
    Harvard Business Review | What's the sexiest job in the 21st century? Harvard Business Review says it's data scientist. With all the messy datasets available to us now, sorting through and processing that information is an opportunity for creativity, ingenuity,and some very sexy computing.
    Full story

  • What the Complete-BGI Merger Really Means

    Sep 26, 2012, 11:45 AM by Michael Croft
    Xconomy | As the dust settles on the BGI-Complete Genomics announcements, we can start to consider what the merger means for the industry and genomics-driven medicine.
    Full story

  • HHMI Names 13 Biomed Research Scholars

    Sep 26, 2012, 02:05 AM by Michael Croft
    HHMI | The Howard Hughes Medical Center has chosen 13 basic researchers as recipients of its Senior International Research Scholar (SIRS) awards. Each research scholar will receive a grant of $100,000 per year over five years.
    Full story

  • BGI and Gates Foundation Collaborate

    Sep 25, 2012, 11:00 AM by Michael Croft
    Bio-IT World | BGI and the Bill & Melinda Gates Foundation have signed a Memorandum of Understanding (MOU) to begin immediate collaboration on global health and agricultural development.
    Full story

  • Data Centers and the Real Infrastructure Behind the Cloud

    Sep 25, 2012, 01:00 AM by Michael Croft
    Bio-IT World Roundup | There's been much discussion this week of data centers and the virtual cloud's actual impact on the environment.
    Full story

  • Phase II Flub for Peregrine

    Sep 24, 2012, 12:55 PM by Michael Croft
    Cancer Grace | A week after releasing favorable Phase II results for the novel vascular-targeting immunotherapy for non-small cell lung cancer, bavituximab, study sponsor Peregrine Pharmaceuticals has announced "major discrepancies" in the trial.
    Full story

  • Vienna Gets Set to Host Bio-IT World Europe 2012

    Sep 24, 2012, 06:55 AM by Michael Croft
    Bio-IT World | Vienna may be known as the City of Music, but in three weeks it will also be a hub for life sciences, informatics, and IT. Bio-IT World’s fourth  European Conference & Expo finds a new home in Vienna, Austria, bringing tracks on drug discovery informatics; data infrastructure and high performance computing; cloud-based bioinformatics and clinical genomics to the heart of Europe.  
    Full story

  • Allen Brain Atlas Reveals Data from First Two Scanned Brains

    Sep 21, 2012, 10:00 AM by Michael Croft
    Forbes | The Allen Brain Atlas published its first results yesterday in Nature, and some were surprising. Gene expression on the right and left sides of the brain looks very similar, but the variety that is there seems to be pretty important.
    Full story

  • Google Ventures has $1 Billion to Spend, Eyes Biotech

    Sep 21, 2012, 09:00 AM by Michael Croft
    CNBC | Google Ventures is planning $1 billion of start-up investment in the next five years and it has its eye on biotech.
    Full story

  • MyoKardia Gains Venture Funds to Investigate Drugs for Genetic Heart Defects

    Sep 21, 2012, 09:00 AM by Michael Croft
    Xconomy | Third Rock Ventures is investing $38 million in a startup that is targeting the genetic causes of heart problems. MyoKardia will set up shop in San Francisco.
    Full story

  • Novartis Takes $665m Bid for Selexys

    Sep 21, 2012, 08:00 AM by Michael Croft
    Tulsa World | In addition to $23 million of Series A financing, Selexys Pharmaceuticals Corp. of Oklahoma City has struck an agreement with Novartis that could lead to the company's acquisition for up to $665 million for its sickle cell treatment.
    Full story

  • Microfluidics, NGS, and Personalized Cosmetics

    Sep 21, 2012, 07:00 AM by Michael Croft
    Bio-IT World Video | Bio-IT World Editor Kevin Davies speaks with Dave Weitz, professor of physics at Harvard and speaker at the upcoming Consumer Genomics Conference, about his research on microfluidics, which has applications in everything from next-gen sequencing technology to personalized cosmetics.
    Full story

  • Foundation Medicine Announces $42.5m in Series B Financing

    Sep 20, 2012, 11:00 AM by Michael Croft
    Boston Globe |  Foundation Medicine announced a $42.5 million Series B financing round this morning thanks to Deerfield Management Company, L.P., Casdin Capital, Redmile Group and strategic investors Roche Venture Fund and WuXi Corporate Venture Fund.
    Full story

  • New Pharma Collaboration Focuses on Clinical Standards

    Sep 20, 2012, 05:20 AM by Michael Croft
    Bio-IT World | A new big pharma collaboration has been launched to identify and solve common drug development challenges, starting with clinical study execution. TransCelerate BioPharma was created by ten companies—Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech (a member of the Roche Group), and Sanofi—all of which have pooled financial, personnel, and other resources to solve industry-wide challenges in a collaborative environment. 
    Full story

  • Illumina Acquires Cytogenetics Company BlueGnome

    Sep 19, 2012, 12:25 PM by Michael Croft
    BlueGnome | Illumina today announced that it will acquire UK company BlueGnome, a cytogenetics company that looks at the structure and function of cells for genetic abnormalities. 
    Full story

  • The Genomics Guinea Pigs

    Sep 19, 2012, 10:45 AM by Michael Croft
    NPR | The researchers who are serving as genomics guinea pigs are also working through how we should process the information the genome reveals.
    Full story

  • Genomic Applications for All

    Sep 18, 2012, 12:40 PM by Michael Croft
    23andMe | 23andMe has released their API to allow developers to design new applications and tools for the 23andMe community accessing 23andMe data.
    Full story

  • Firms Charge Fiduciary Breach in BGI-Complete Merger

    Sep 18, 2012, 12:25 PM by Michael Croft
    Bio-IT World | The announcement on Monday that Complete Genomics will be acquired by BGI for $117.6 million has left many surprised and dismayed. A slew of firms have announced investigations of the Complete Genomics Board of Directors contending that the $3.15/share price may not be "fair". 
    Full story

  • Biotech Making Friends with Twitter

    Sep 18, 2012, 09:45 AM by Michael Croft
    Xconomy | Biotech comes into its own on Twitter. Luke Timmerman of Xconomy discusses the advantages for the industry.
    Full story

  • Craigslist Helps Reveal Flu Antibody

    Sep 17, 2012, 16:00 PM by Michael Croft
    UT San Diego | Researchers from the Scripps Research Institute in La Jolla and Sea Lane Biotechnologies have identified an antibody that protects cells from the influenza virus with the help of Craigslist donors.
    Full story